Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory

Shanghai Institute of Pharmaceutical Industry

Zhe Jiang Medicine Co., Ltd

Zhejiang Changhai Pharmaceutical Co., Ltd.

Guofeng Wu

Jun Wang

Weidong Ye

Weicheng Zhou

Runpu Shen

Xiaohua Song

Chunlei Lv

Xiaoyue Jiang

Zhengyan Cai

Zhanggui Wu

Xufeng Wu

Dadong Shen

Yongmei Xu

Wei Mao

Kuaile Lin

Chunlin Chen

Gang Fan

Haoling Gao

Jinna Cai

Li Sheng

Xiaoqin Lin

Lanfang Zhu

Jing Pan

Sen Xiao

Lirong Yue

Lili Lv

Yunxia Gong

Long Chen

Yuquan Luo

Lin Zhao

Junwei Chen

Provided in the present disclosure are a nemonoxacin malate active pharmaceutical ingredient with low combination impurities, and a preparation method thereof, specifically, provided in the present disclosure is a method for preparing the nemonoxacin malate active pharmaceutical ingredient, the method includes the following steps: 1) providing a C1-C3 alcohol/water mixed solvent in which nemonoxacin free base (Formula II) and D,L-malic acid are dissolved; and 2) performing cooling crystallization on a mixed solution obtained in the step 1), and then performing solid-liquid separation, washing and drying on a precipitated solid, so as to obtain the nemonoxacin malate active pharmaceutical ingredient.

Nemonoxacin malate active pharmaceutical ingredient with low combination impurities, and a preparation method thereof

The present invention provides a method for preparing an intermediate compound of sitagliptin represented by formula I. The preparation method comprises: dissolving a compound represented by formula II into an organic solvent; and under the catalysis of fatty acid and effect of chlorosilane, performing a reduction reaction of carbon-carbon double bonds, so as to obtain the intermediate compound of sitagliptin represented by formula I, R being methyl or formoxyl. The preparation method of the present invention avoids precious metal as a catalyst, and accordingly, the cost is low, the post-treatment is simple, the product has a high yield, chemical purity and optical purity, and de % is greater than 99.6%, and the preparation method can be used in synthesis of sitagliptin and is suitable for industrial production. 

Method for preparing a sitagliptin intermediate

The present invention provides a 2, 6-di-nitrogen-containing substituted purine derivative having a formula (I) structure, or pharmaceutical salt or hydrate thereof, and preparation method and use thereof. The compound is broad spectrum anticancer, low toxicity, high anticancer activity and good stability. 

2, 6-Di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof

Provided are a linezolid intermediate and the preparation method thereof and a method for synthesizing linezolid. The structure of the intermediate is shown as formula F2, wherein the compound is prepared by a condensation reaction of (S)&#x2014;N-(3-chloro-2-hydroxy-1-propyl) acetamide and the compound shown in formula F4. In the preparation methods of the compound shown in formula F2 and linezolid, the reaction system is mild, side reactions are few and the product yield is high. 

Linezolid intermediate and method for synthesizing linezolid

Growing community of inventors

Xinchang County, China

Guofeng Wu